COIOSDeep risk insights through multi-disciplinary research across the globe
a row of buildings on a city street
Item new Peer-reviewed Added

Nitazene analogues in US overdose deaths, 2019 to 2025

Nitazene analogues were detected in 1,443 US overdose deaths in 2019–2024, often with illegally made fentanyls.

The study described US overdose deaths in which nitazene analogues were detected. It used CDC's SUDORS data for 2019–2024 and data from two forensic toxicology laboratories to the third quarter of 2025. Nitazene analogues were detected in 1,443 overdose deaths across 47 jurisdictions during 2019–2024. Isotonitazene, metonitazene and protonitazene were among the most common, often co-detected with illegally made fentanyls, stimulants and illegal benzodiazepines. Compared with other opioid deaths, they more often showed injection drug use, prior overdose and prior substance use disorder treatment. Routine toxicology testing for nitazenes is limited, so the counts are likely to be underestimates.

Why it is interesting: Nitazenes are highly potent synthetic opioids that routine toxicology often misses. Laboratory data often identified new analogues earlier, or in higher initial numbers, than national surveillance.

Source
International Journal of Drug Policy, 20 November 2026
Paper
Nitazene analogs in unintentional and undetermined intent drug overdose deaths - United States, 2019-2025
Authors
Zlotorzynska M, Krotulski AJ, Quader ZS, Gladden RM, Papsun DM, Logan BK et al.
DOI
10.1016/j.drugpo.2026.105588
Type
Peer-reviewed article
Design
Descriptive surveillance analysis linking CDC SUDORS (1443 nitazene-detected overdose deaths, 47 jurisdictions, 2019-2024) with two forensic toxicology laboratory series through Q3 2025
Verdict
New finding
Driver
Alcohol and drug use
Abstract — the authors' own words, CC BY

Nitazene analogs have emerged as a class of synthetic opioids in the illegal drug supply, presenting challenges for overdose surveillance, forensic detection, and public health response due to high potency, structural diversity, and limited routine toxicology testing. We analyzed data from CDC's State Unintentional Drug Overdose Reporting System (SUDORS) and two forensic toxicology laboratories, the Center for Forensic Science Research and Education (CFSRE) and NMS Labs, to describe trends and characteristics of overdose deaths with nitazene analogs detected. Quarterly trends were assessed during 2019-2024 for SUDORS data and through the third quarter of 2025 for CFSRE/NMS Labs data. Analyses of SUDORS data examined drug co-detection, demographics, and overdose circumstances. During 2019-2024, nitazene analogs were detected in 1443 overdose deaths across 47 jurisdictions, with isotonitazene, metonitazene, protonitazene, N-pyrrolidino etonitazene and N-pyrrolidino protonitazene most commonly detected. Detection patterns varied over time by analog. Substances were often identified earlier or in higher initial numbers in forensic laboratory data before appearing in SUDORS. Co-detection with illegally-made fentanyls, stimulants, and illegal benzodiazepines was common. Compared with overdose deaths with other opioids detected, deaths with nitazene analogs more often had evidence of injection drug use, prior overdose, and prior substance use disorder treatment. Nitazene analogs represent a persistent and evolving overdose threat that is likely under-detected in routine surveillance. Integrating complementary forensic and public health data sources can improve identification of emerging substances. Expanding toxicology capacity, innovative surveillance, and targeted overdose prevention strategies are critical to mitigating adverse outcomes associated with highly potent substances.

Other drivers in Behavioural science